A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD. We are also developing potential therapeutic candidates through our partnered program with Arrowhead for the treatment of Facioscapulohumeral muscular dystrophy ("FSHD"), myotonic dystrophy type 1 (“DM1”), Spinocerebellar ataxia ("SCA"), Idiopathic Pulmonary Fibrosis ("IPF"), Huntington's disease and other neuromuscular and skeletal diseases.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.2B | 1.9B | 1.2B | 933M | 702M |
| Net Income | -713M | -713M | 235M | -536M | -703M | -419M |
| EPS | $-7.13 | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
| Free Cash Flow | -307M | -307M | -343M | -577M | -356M | -482M |
| ROIC | -40.1% | -30.8% | 19.3% | -26.6% | -41.1% | -32.9% |
| Gross Margin | 63.5% | 63.5% | 86.0% | 72.8% | 78.6% | 99.1% |
| Debt/Equity | 0.91 | 0.91 | 0.88 | 1.75 | 4.20 | 0.67 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -700M | -700M | 218M | -268M | -536M | -460M |
| Operating Margin | -31.8% | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% |
| ROE | -62.5% | -53.5% | 19.7% | -86.2% | -107.2% | -49.6% |
| Shares Outstanding | 100M | 100M | 101M | 92M | 88M | 81M |
Sarepta Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 80.0%. Total shareholder yield (buybacks) is 1.1%. At current prices, the estimated annualized return to fair value is +6.0%.
Sarepta Therapeutics, Inc. (SRPT) has a 5-year average return on invested capital (ROIC) of -22.4%. This is below average and may indicate limited pricing power.
Sarepta Therapeutics, Inc. (SRPT) has a market capitalization of $2.2B. It is classified as a mid-cap stock.
Sarepta Therapeutics, Inc. (SRPT) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.13%.
Sarepta Therapeutics, Inc. (SRPT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Sarepta Therapeutics, Inc. (SRPT) reported annual revenue of $2.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Sarepta Therapeutics, Inc. (SRPT) has a net profit margin of -32.5%. The company is currently unprofitable.
Sarepta Therapeutics, Inc. (SRPT) generated $-307 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Sarepta Therapeutics, Inc. (SRPT) has a debt-to-equity ratio of 0.91. This indicates moderate leverage.
Sarepta Therapeutics, Inc. (SRPT) reported earnings per share (EPS) of $-7.13 in its most recent fiscal year.
Sarepta Therapeutics, Inc. (SRPT) has a return on equity (ROE) of -53.5%. A negative ROE may indicate losses or negative equity.
Sarepta Therapeutics, Inc. (SRPT) has a 5-year average gross margin of 80.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Sarepta Therapeutics, Inc. (SRPT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sarepta Therapeutics, Inc. (SRPT) has a book value per share of $11.40, based on its most recent annual SEC filing.